Pacific Biosciences of California, Inc. (NASDAQ: PACB) Stock Competitors & Peer Comparison
See PACB's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PACB and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PACB | $1.83 | +12.65% | 531.1M | -4.17 | -$0.41 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $100.82 | -0.46% | 174.7B | 19.38 | $5.21 | +2.46% |
| MDT | $87.27 | -1.55% | 114.5B | 16.18 | $5.53 | +3.22% |
| SYK | $277.59 | +1.92% | 105.6B | 20.57 | $13.39 | +1.27% |
| BSX | $43.37 | -1.25% | 65.6B | 14.23 | $3.10 | N/A |
| EW | $87.96 | +1.94% | 50B | 32.16 | $2.70 | N/A |
| DXCM | $86.45 | -0.20% | 32.7B | 33.99 | $2.55 | N/A |
| GEHC | $66.22 | -0.62% | 30.2B | 14.64 | $4.56 | +0.21% |
| PHG | $24.67 | -1.16% | 24.5B | 14.35 | $1.75 | +3.94% |
Stock Comparison
Boston Scientific Corporation (NYSE: BSX-PA)
PACB vs BSX-PA Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, PACB's ROE is -49.62%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, PACB is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for PACB.Check BSX-PA's competition here
Abbott Laboratories (NYSE: ABT)
PACB vs ABT Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, ABT has a market cap of 174.7B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while ABT trades at $100.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas ABT's P/E ratio is 19.38. In terms of profitability, PACB's ROE is -49.62%, compared to ABT's ROE of +0.11%. Regarding short-term risk, PACB is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for PACB.Check ABT's competition here
Medtronic plc (NYSE: MDT)
PACB vs MDT Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, MDT has a market cap of 114.5B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while MDT trades at $87.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas MDT's P/E ratio is 16.18. In terms of profitability, PACB's ROE is -49.62%, compared to MDT's ROE of +0.11%. Regarding short-term risk, PACB is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for PACB.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
PACB vs SYK Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, SYK has a market cap of 105.6B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while SYK trades at $277.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas SYK's P/E ratio is 20.57. In terms of profitability, PACB's ROE is -49.62%, compared to SYK's ROE of +0.16%. Regarding short-term risk, PACB is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for PACB.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
PACB vs BSX Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, BSX has a market cap of 65.6B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while BSX trades at $43.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas BSX's P/E ratio is 14.23. In terms of profitability, PACB's ROE is -49.62%, compared to BSX's ROE of +0.15%. Regarding short-term risk, PACB is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for PACB.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
PACB vs EW Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, EW has a market cap of 50B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while EW trades at $87.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas EW's P/E ratio is 32.16. In terms of profitability, PACB's ROE is -49.62%, compared to EW's ROE of +0.10%. Regarding short-term risk, PACB is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for PACB.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
PACB vs DXCM Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, DXCM has a market cap of 32.7B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while DXCM trades at $86.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas DXCM's P/E ratio is 33.99. In terms of profitability, PACB's ROE is -49.62%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, PACB is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for PACB.Check DXCM's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
PACB vs GEHC Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, GEHC has a market cap of 30.2B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while GEHC trades at $66.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas GEHC's P/E ratio is 14.64. In terms of profitability, PACB's ROE is -49.62%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, PACB is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for PACB.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
PACB vs PHG Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, PHG has a market cap of 24.5B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while PHG trades at $24.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas PHG's P/E ratio is 14.35. In terms of profitability, PACB's ROE is -49.62%, compared to PHG's ROE of +0.10%. Regarding short-term risk, PACB is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for PACB.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
PACB vs ZBH Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, ZBH has a market cap of 17.7B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while ZBH trades at $90.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas ZBH's P/E ratio is 10.80. In terms of profitability, PACB's ROE is -49.62%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, PACB is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for PACB.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
PACB vs ABMD Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas ABMD's P/E ratio is 65.36. In terms of profitability, PACB's ROE is -49.62%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, PACB is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for PACB.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
PACB vs PEN Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while PEN trades at $318.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas PEN's P/E ratio is 83.31. In terms of profitability, PACB's ROE is -49.62%, compared to PEN's ROE of +0.11%. Regarding short-term risk, PACB is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for PACB.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
PACB vs SWAV Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas SWAV's P/E ratio is 78.76. In terms of profitability, PACB's ROE is -49.62%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, PACB is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for PACB.Check SWAV's competition here
Smith & Nephew plc (NYSE: SNN)
PACB vs SNN Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, SNN has a market cap of 11.4B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while SNN trades at $26.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas SNN's P/E ratio is 18.28. In terms of profitability, PACB's ROE is -49.62%, compared to SNN's ROE of +0.12%. Regarding short-term risk, PACB is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for PACB.Check SNN's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
PACB vs BIO-B Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, BIO-B has a market cap of 10.5B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while BIO-B trades at $385.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas BIO-B's P/E ratio is -67.89. In terms of profitability, PACB's ROE is -49.62%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, PACB is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for PACB.Check BIO-B's competition here
Align Technology, Inc. (NASDAQ: ALGN)
PACB vs ALGN Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, ALGN has a market cap of 10.4B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while ALGN trades at $143.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas ALGN's P/E ratio is 13.22. In terms of profitability, PACB's ROE is -49.62%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, PACB is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for PACB.Check ALGN's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
PACB vs BIO Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, BIO has a market cap of 10.2B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while BIO trades at $380.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas BIO's P/E ratio is 40.70. In terms of profitability, PACB's ROE is -49.62%, compared to BIO's ROE of +0.03%. Regarding short-term risk, PACB is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for PACB.Check BIO's competition here
Globus Medical, Inc. (NYSE: GMED)
PACB vs GMED Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, GMED has a market cap of 10.1B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while GMED trades at $75.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas GMED's P/E ratio is 16.84. In terms of profitability, PACB's ROE is -49.62%, compared to GMED's ROE of +0.12%. Regarding short-term risk, PACB is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for PACB.Check GMED's competition here
Bruker Corporation (NASDAQ: BRKR)
PACB vs BRKR Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, BRKR has a market cap of 9.6B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while BRKR trades at $64.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas BRKR's P/E ratio is 31.80. In terms of profitability, PACB's ROE is -49.62%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, PACB is more volatile compared to BRKR. This indicates higher risk in terms of short-term price fluctuations for PACB.Check BRKR's competition here
Masimo Corporation (NASDAQ: MASI)
PACB vs MASI Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas MASI's P/E ratio is 44.43. In terms of profitability, PACB's ROE is -49.62%, compared to MASI's ROE of +0.09%. Regarding short-term risk, PACB is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for PACB.Check MASI's competition here
Glaukos Corporation (NYSE: GKOS)
PACB vs GKOS Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, GKOS has a market cap of 9.3B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while GKOS trades at $158.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas GKOS's P/E ratio is -184.31. In terms of profitability, PACB's ROE is -49.62%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, PACB is more volatile compared to GKOS. This indicates higher risk in terms of short-term price fluctuations for PACB.Check GKOS's competition here
Bruker Corporation (NASDAQ: BRKRP)
PACB vs BRKRP Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, BRKRP has a market cap of 9.3B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while BRKRP trades at $471.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas BRKRP's P/E ratio is 251.76. In terms of profitability, PACB's ROE is -49.62%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, PACB is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for PACB.Check BRKRP's competition here
Insulet Corp. (NASDAQ: PODD)
PACB vs PODD Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, PODD has a market cap of 9.2B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while PODD trades at $132.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas PODD's P/E ratio is 22.68. In terms of profitability, PACB's ROE is -49.62%, compared to PODD's ROE of +0.27%. Regarding short-term risk, PACB is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for PACB.Check PODD's competition here
Haemonetics Corporation (NYSE: HAE)
PACB vs HAE Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, HAE has a market cap of 4.8B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while HAE trades at $105.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas HAE's P/E ratio is 21.13. In terms of profitability, PACB's ROE is -49.62%, compared to HAE's ROE of +0.11%. Regarding short-term risk, PACB is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for PACB.Check HAE's competition here
Inari Medical, Inc. (NASDAQ: NARI)
PACB vs NARI Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas NARI's P/E ratio is -59.24. In terms of profitability, PACB's ROE is -49.62%, compared to NARI's ROE of -0.00%. Regarding short-term risk, PACB is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for PACB.Check NARI's competition here
Integer Holdings Corporation (NYSE: ITGR)
PACB vs ITGR Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while ITGR trades at $126.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas ITGR's P/E ratio is 19.90. In terms of profitability, PACB's ROE is -49.62%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, PACB is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for PACB.Check ITGR's competition here
LivaNova PLC (NASDAQ: LIVN)
PACB vs LIVN Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, LIVN has a market cap of 4.2B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while LIVN trades at $76.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas LIVN's P/E ratio is 18.34. In terms of profitability, PACB's ROE is -49.62%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, PACB is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for PACB.Check LIVN's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
PACB vs IRTC Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, IRTC has a market cap of 3.7B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while IRTC trades at $111.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas IRTC's P/E ratio is -261.86. In terms of profitability, PACB's ROE is -49.62%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, PACB is more volatile compared to IRTC. This indicates higher risk in terms of short-term price fluctuations for PACB.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
PACB vs AXNX Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas AXNX's P/E ratio is -709.80. In terms of profitability, PACB's ROE is -49.62%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, PACB is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for PACB.Check AXNX's competition here
Neogen Corporation (NASDAQ: NEOG)
PACB vs NEOG Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, NEOG has a market cap of 3B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while NEOG trades at $13.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas NEOG's P/E ratio is 49.00. In terms of profitability, PACB's ROE is -49.62%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, PACB is more volatile compared to NEOG. This indicates higher risk in terms of short-term price fluctuations for PACB.Check NEOG's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
PACB vs TMDX Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, TMDX has a market cap of 2.9B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while TMDX trades at $83.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas TMDX's P/E ratio is 41.99. In terms of profitability, PACB's ROE is -49.62%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, PACB is more volatile compared to TMDX. This indicates higher risk in terms of short-term price fluctuations for PACB.Check TMDX's competition here
Butterfly Network, Inc. (NYSE: BFLY)
PACB vs BFLY Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, BFLY has a market cap of 2.4B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while BFLY trades at $9.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas BFLY's P/E ratio is -38.10. In terms of profitability, PACB's ROE is -49.62%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, PACB is more volatile compared to BFLY. This indicates higher risk in terms of short-term price fluctuations for PACB.Check BFLY's competition here
AxoGen, Inc. (NASDAQ: AXGN)
PACB vs AXGN Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while AXGN trades at $42.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas AXGN's P/E ratio is 114.11. In terms of profitability, PACB's ROE is -49.62%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, PACB is more volatile compared to AXGN. This indicates higher risk in terms of short-term price fluctuations for PACB.Check AXGN's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
PACB vs UFPT Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, UFPT has a market cap of 2.3B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while UFPT trades at $296.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas UFPT's P/E ratio is 30.56. In terms of profitability, PACB's ROE is -49.62%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, PACB is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for PACB.Check UFPT's competition here
NuVasive, Inc. (NASDAQ: NUVA)
PACB vs NUVA Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas NUVA's P/E ratio is 75.00. In terms of profitability, PACB's ROE is -49.62%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, PACB is more volatile compared to NUVA. This indicates higher risk in terms of short-term price fluctuations for PACB.Check NUVA's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
PACB vs INSP Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, INSP has a market cap of 2B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while INSP trades at $71.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas INSP's P/E ratio is 30.84. In terms of profitability, PACB's ROE is -49.62%, compared to INSP's ROE of +0.18%. Regarding short-term risk, PACB is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for PACB.Check INSP's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
PACB vs ESTA Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, ESTA has a market cap of 1.9B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while ESTA trades at $62.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas ESTA's P/E ratio is -51.86. In terms of profitability, PACB's ROE is -49.62%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, PACB is more volatile compared to ESTA. This indicates higher risk in terms of short-term price fluctuations for PACB.Check ESTA's competition here
Novocure Ltd (NASDAQ: NVCR)
PACB vs NVCR Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, NVCR has a market cap of 1.8B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while NVCR trades at $15.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas NVCR's P/E ratio is -12.18. In terms of profitability, PACB's ROE is -49.62%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, PACB is more volatile compared to NVCR. This indicates higher risk in terms of short-term price fluctuations for PACB.Check NVCR's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
PACB vs ATEC Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while ATEC trades at $10.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas ATEC's P/E ratio is -167.50. In terms of profitability, PACB's ROE is -49.62%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, PACB is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for PACB.Check ATEC's competition here
CONMED Corporation (NYSE: CNMD)
PACB vs CNMD Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while CNMD trades at $46.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas CNMD's P/E ratio is 10.20. In terms of profitability, PACB's ROE is -49.62%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, PACB is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for PACB.Check CNMD's competition here
Heska Corporation (NASDAQ: HSKA)
PACB vs HSKA Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas HSKA's P/E ratio is -62.49. In terms of profitability, PACB's ROE is -49.62%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, PACB is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for PACB.Check HSKA's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
PACB vs IART Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while IART trades at $16.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas IART's P/E ratio is 6.89. In terms of profitability, PACB's ROE is -49.62%, compared to IART's ROE of -0.01%. Regarding short-term risk, PACB is more volatile compared to IART. This indicates higher risk in terms of short-term price fluctuations for PACB.Check IART's competition here
Avanos Medical, Inc. (NYSE: AVNS)
PACB vs AVNS Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas AVNS's P/E ratio is 27.77. In terms of profitability, PACB's ROE is -49.62%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, PACB is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for PACB.Check AVNS's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
PACB vs TNDM Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while TNDM trades at $16.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas TNDM's P/E ratio is -17.66. In terms of profitability, PACB's ROE is -49.62%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, PACB is more volatile compared to TNDM. This indicates higher risk in terms of short-term price fluctuations for PACB.Check TNDM's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
PACB vs SILK Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas SILK's P/E ratio is -18.96. In terms of profitability, PACB's ROE is -49.62%, compared to SILK's ROE of -0.35%. Regarding short-term risk, PACB is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for PACB.Check SILK's competition here
Artivion, Inc. (NYSE: AORT)
PACB vs AORT Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while AORT trades at $22.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas AORT's P/E ratio is 38.23. In terms of profitability, PACB's ROE is -49.62%, compared to AORT's ROE of -0.01%. Regarding short-term risk, PACB is more volatile compared to AORT. This indicates higher risk in terms of short-term price fluctuations for PACB.Check AORT's competition here
IRadimed Corporation (NASDAQ: IRMD)
PACB vs IRMD Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while IRMD trades at $85.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas IRMD's P/E ratio is 43.55. In terms of profitability, PACB's ROE is -49.62%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, PACB is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for PACB.Check IRMD's competition here
Paragon 28, Inc. (NYSE: FNA)
PACB vs FNA Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas FNA's P/E ratio is -19.83. In terms of profitability, PACB's ROE is -49.62%, compared to FNA's ROE of -0.35%. Regarding short-term risk, PACB is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for PACB.Check FNA's competition here
Enovis Corporation (NYSE: ENOV)
PACB vs ENOV Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, ENOV has a market cap of 1B. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while ENOV trades at $18.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas ENOV's P/E ratio is 5.20. In terms of profitability, PACB's ROE is -49.62%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, PACB is more volatile compared to ENOV. This indicates higher risk in terms of short-term price fluctuations for PACB.Check ENOV's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
PACB vs PRCT Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, PRCT has a market cap of 981.9M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while PRCT trades at $18.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas PRCT's P/E ratio is -8.89. In terms of profitability, PACB's ROE is -49.62%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, PACB is more volatile compared to PRCT. This indicates higher risk in terms of short-term price fluctuations for PACB.Check PRCT's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
PACB vs LMRI Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, LMRI has a market cap of 974.7M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while LMRI trades at $10.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas LMRI's P/E ratio is -19.74. In terms of profitability, PACB's ROE is -49.62%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, PACB is more volatile compared to LMRI. This indicates higher risk in terms of short-term price fluctuations for PACB.Check LMRI's competition here
Bioventus Inc. (NASDAQ: BVS)
PACB vs BVS Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, BVS has a market cap of 949.8M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while BVS trades at $13.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas BVS's P/E ratio is 18.45. In terms of profitability, PACB's ROE is -49.62%, compared to BVS's ROE of +0.28%. Regarding short-term risk, PACB is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for PACB.Check BVS's competition here
CeriBell, Inc. (NASDAQ: CBLL)
PACB vs CBLL Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, CBLL has a market cap of 930M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while CBLL trades at $24.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas CBLL's P/E ratio is -13.93. In terms of profitability, PACB's ROE is -49.62%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, PACB is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for PACB.Check CBLL's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
PACB vs BBNX Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, BBNX has a market cap of 923.2M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while BBNX trades at $19.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas BBNX's P/E ratio is -12.44. In terms of profitability, PACB's ROE is -49.62%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, PACB is more volatile compared to BBNX. This indicates higher risk in terms of short-term price fluctuations for PACB.Check BBNX's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
PACB vs CSII Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas CSII's P/E ratio is -20.83. In terms of profitability, PACB's ROE is -49.62%, compared to CSII's ROE of -0.14%. Regarding short-term risk, PACB is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for PACB.Check CSII's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
PACB vs SIBN Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, SIBN has a market cap of 832M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while SIBN trades at $18.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas SIBN's P/E ratio is -55.18. In terms of profitability, PACB's ROE is -49.62%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, PACB is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for PACB.Check SIBN's competition here
InMode Ltd. (NASDAQ: INMD)
PACB vs INMD Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, INMD has a market cap of 816.5M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while INMD trades at $14.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas INMD's P/E ratio is 9.86. In terms of profitability, PACB's ROE is -49.62%, compared to INMD's ROE of +0.12%. Regarding short-term risk, PACB is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for PACB.Check INMD's competition here
Varex Imaging Corporation (NASDAQ: VREX)
PACB vs VREX Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, VREX has a market cap of 777.2M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while VREX trades at $18.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas VREX's P/E ratio is 19.43. In terms of profitability, PACB's ROE is -49.62%, compared to VREX's ROE of +0.05%. Regarding short-term risk, PACB is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for PACB.Check VREX's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
PACB vs AHCO Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, AHCO has a market cap of 768.7M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while AHCO trades at $5.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas AHCO's P/E ratio is 11.53. In terms of profitability, PACB's ROE is -49.62%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, PACB is more volatile compared to AHCO. This indicates higher risk in terms of short-term price fluctuations for PACB.Check AHCO's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
PACB vs AVR Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, AVR has a market cap of 752.6M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while AVR trades at $7.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas AVR's P/E ratio is -3.99. In terms of profitability, PACB's ROE is -49.62%, compared to AVR's ROE of -0.78%. Regarding short-term risk, PACB is more volatile compared to AVR. This indicates higher risk in terms of short-term price fluctuations for PACB.Check AVR's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
PACB vs CTKB Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, CTKB has a market cap of 741.3M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while CTKB trades at $5.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas CTKB's P/E ratio is -30.41. In terms of profitability, PACB's ROE is -49.62%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, PACB is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for PACB.Check CTKB's competition here
Surmodics, Inc. (NASDAQ: SRDX)
PACB vs SRDX Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas SRDX's P/E ratio is -34.66. In terms of profitability, PACB's ROE is -49.62%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, PACB is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for PACB.Check SRDX's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
PACB vs KIDS Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, KIDS has a market cap of 580M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while KIDS trades at $22.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas KIDS's P/E ratio is -19.14. In terms of profitability, PACB's ROE is -49.62%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, PACB is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for PACB.Check KIDS's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
PACB vs APEN Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas APEN's P/E ratio is -9.43. In terms of profitability, PACB's ROE is -49.62%, compared to APEN's ROE of -0.85%. Regarding short-term risk, PACB is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for PACB.Check APEN's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
PACB vs SSII Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, SSII has a market cap of 578.4M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while SSII trades at $2.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas SSII's P/E ratio is -48.17. In terms of profitability, PACB's ROE is -49.62%, compared to SSII's ROE of -0.27%. Regarding short-term risk, PACB is more volatile compared to SSII. This indicates higher risk in terms of short-term price fluctuations for PACB.Check SSII's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
PACB vs DCTH Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, DCTH has a market cap of 545.8M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while DCTH trades at $15.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas DCTH's P/E ratio is 1581.00. In terms of profitability, PACB's ROE is -49.62%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, PACB is more volatile compared to DCTH. This indicates higher risk in terms of short-term price fluctuations for PACB.Check DCTH's competition here
ZimVie Inc. (NASDAQ: ZIMV)
PACB vs ZIMV Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, PACB's ROE is -49.62%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, PACB is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for PACB.Check ZIMV's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
PACB vs TCMD Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, TCMD has a market cap of 514.7M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while TCMD trades at $22.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas TCMD's P/E ratio is 21.13. In terms of profitability, PACB's ROE is -49.62%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, PACB is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for PACB.Check TCMD's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
PACB vs SGHT Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, SGHT has a market cap of 504.4M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while SGHT trades at $9.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas SGHT's P/E ratio is -16.55. In terms of profitability, PACB's ROE is -49.62%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, PACB is more volatile compared to SGHT. This indicates higher risk in terms of short-term price fluctuations for PACB.Check SGHT's competition here
Cerus Corporation (NASDAQ: CERS)
PACB vs CERS Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, CERS has a market cap of 493.7M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while CERS trades at $2.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas CERS's P/E ratio is -81.40. In terms of profitability, PACB's ROE is -49.62%, compared to CERS's ROE of -0.10%. Regarding short-term risk, PACB is more volatile compared to CERS. This indicates higher risk in terms of short-term price fluctuations for PACB.Check CERS's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
PACB vs NPCE Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, NPCE has a market cap of 482.4M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while NPCE trades at $14.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas NPCE's P/E ratio is -24.82. In terms of profitability, PACB's ROE is -49.62%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, PACB is more volatile compared to NPCE. This indicates higher risk in terms of short-term price fluctuations for PACB.Check NPCE's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
PACB vs CLPT Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, CLPT has a market cap of 459.1M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while CLPT trades at $12.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas CLPT's P/E ratio is -12.97. In terms of profitability, PACB's ROE is -49.62%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, PACB is more volatile compared to CLPT. This indicates higher risk in terms of short-term price fluctuations for PACB.Check CLPT's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
PACB vs SENS Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, SENS has a market cap of 411.3M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while SENS trades at $10.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas SENS's P/E ratio is -4.41. In terms of profitability, PACB's ROE is -49.62%, compared to SENS's ROE of -1.66%. Regarding short-term risk, PACB is more volatile compared to SENS. This indicates higher risk in terms of short-term price fluctuations for PACB.Check SENS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
PACB vs OFIX Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, OFIX has a market cap of 397.7M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while OFIX trades at $9.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas OFIX's P/E ratio is -6.41. In terms of profitability, PACB's ROE is -49.62%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, PACB is more volatile compared to OFIX. This indicates higher risk in terms of short-term price fluctuations for PACB.Check OFIX's competition here
CapsoVision, Inc. (NASDAQ: CV)
PACB vs CV Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, CV has a market cap of 345.7M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while CV trades at $6.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas CV's P/E ratio is -10.98. In terms of profitability, PACB's ROE is -49.62%, compared to CV's ROE of -1.78%. Regarding short-term risk, PACB is more volatile compared to CV. This indicates higher risk in terms of short-term price fluctuations for PACB.Check CV's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
PACB vs SMLR Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas SMLR's P/E ratio is 3.92. In terms of profitability, PACB's ROE is -49.62%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, PACB is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for PACB.Check SMLR's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
PACB vs TMCI Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, TMCI has a market cap of 290.6M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while TMCI trades at $4.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas TMCI's P/E ratio is -4.77. In terms of profitability, PACB's ROE is -49.62%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, PACB is more volatile compared to TMCI. This indicates higher risk in terms of short-term price fluctuations for PACB.Check TMCI's competition here
Avita Medical Inc. (NASDAQ: RCEL)
PACB vs RCEL Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, RCEL has a market cap of 289.9M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while RCEL trades at $12.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas RCEL's P/E ratio is -8.10. In terms of profitability, PACB's ROE is -49.62%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, PACB is more volatile compared to RCEL. This indicates higher risk in terms of short-term price fluctuations for PACB.Check RCEL's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
PACB vs CATX Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, CATX has a market cap of 286.3M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while CATX trades at $2.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas CATX's P/E ratio is -1.89. In terms of profitability, PACB's ROE is -49.62%, compared to CATX's ROE of -0.42%. Regarding short-term risk, PACB is more volatile compared to CATX. This indicates higher risk in terms of short-term price fluctuations for PACB.Check CATX's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
PACB vs TLSI Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, TLSI has a market cap of 270.3M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while TLSI trades at $4.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas TLSI's P/E ratio is -2.61. In terms of profitability, PACB's ROE is -49.62%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, PACB is more volatile compared to TLSI. This indicates higher risk in terms of short-term price fluctuations for PACB.Check TLSI's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
PACB vs INFU Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, INFU has a market cap of 259.4M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while INFU trades at $12.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas INFU's P/E ratio is 31.35. In terms of profitability, PACB's ROE is -49.62%, compared to INFU's ROE of +0.15%. Regarding short-term risk, PACB is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for PACB.Check INFU's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
PACB vs MGRM Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas MGRM's P/E ratio is -12.00. In terms of profitability, PACB's ROE is -49.62%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, PACB is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for PACB.Check MGRM's competition here
Electromed, Inc. (AMEX: ELMD)
PACB vs ELMD Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, ELMD has a market cap of 233.3M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while ELMD trades at $27.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas ELMD's P/E ratio is 21.51. In terms of profitability, PACB's ROE is -49.62%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, PACB is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for PACB.Check ELMD's competition here
Nevro Corp. (NYSE: NVRO)
PACB vs NVRO Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas NVRO's P/E ratio is -1.91. In terms of profitability, PACB's ROE is -49.62%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, PACB is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for PACB.Check NVRO's competition here
Profound Medical Corp. (NASDAQ: PROF)
PACB vs PROF Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, PROF has a market cap of 215.1M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while PROF trades at $5.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas PROF's P/E ratio is -6.04. In terms of profitability, PACB's ROE is -49.62%, compared to PROF's ROE of -0.56%. Regarding short-term risk, PACB is more volatile compared to PROF. This indicates higher risk in terms of short-term price fluctuations for PACB.Check PROF's competition here
RxSight, Inc. (NASDAQ: RXST)
PACB vs RXST Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, RXST has a market cap of 193.3M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while RXST trades at $4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas RXST's P/E ratio is -4.13. In terms of profitability, PACB's ROE is -49.62%, compared to RXST's ROE of -0.17%. Regarding short-term risk, PACB is more volatile compared to RXST. This indicates higher risk in terms of short-term price fluctuations for PACB.Check RXST's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
PACB vs BSGM Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas BSGM's P/E ratio is -5.81. In terms of profitability, PACB's ROE is -49.62%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, PACB is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for PACB.Check BSGM's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
PACB vs MDGS Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas MDGS's P/E ratio is -0.27. In terms of profitability, PACB's ROE is -49.62%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, PACB is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for PACB.Check MDGS's competition here
Neuronetics, Inc. (NASDAQ: STIM)
PACB vs STIM Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, STIM has a market cap of 177.8M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while STIM trades at $2.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas STIM's P/E ratio is -5.81. In terms of profitability, PACB's ROE is -49.62%, compared to STIM's ROE of -1.51%. Regarding short-term risk, PACB is more volatile compared to STIM. This indicates higher risk in terms of short-term price fluctuations for PACB.Check STIM's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
PACB vs FOCL Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, FOCL has a market cap of 169.8M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while FOCL trades at $4.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas FOCL's P/E ratio is -4.38. In terms of profitability, PACB's ROE is -49.62%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, PACB is more volatile compared to FOCL. This indicates higher risk in terms of short-term price fluctuations for PACB.Check FOCL's competition here
Quanterix Corporation (NASDAQ: QTRX)
PACB vs QTRX Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, QTRX has a market cap of 165.8M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while QTRX trades at $3.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas QTRX's P/E ratio is -1.39. In terms of profitability, PACB's ROE is -49.62%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, PACB is more volatile compared to QTRX. This indicates higher risk in terms of short-term price fluctuations for PACB.Check QTRX's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
PACB vs QIPT Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas QIPT's P/E ratio is -15.87. In terms of profitability, PACB's ROE is -49.62%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, PACB is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for PACB.Check QIPT's competition here
Quantum-Si incorporated (NASDAQ: QSI)
PACB vs QSI Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, QSI has a market cap of 157.3M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while QSI trades at $0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas QSI's P/E ratio is -1.73. In terms of profitability, PACB's ROE is -49.62%, compared to QSI's ROE of -0.47%. Regarding short-term risk, PACB is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for PACB.Check QSI's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
PACB vs LUCD Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, LUCD has a market cap of 153.7M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while LUCD trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas LUCD's P/E ratio is -2.18. In terms of profitability, PACB's ROE is -49.62%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, PACB is more volatile compared to LUCD. This indicates higher risk in terms of short-term price fluctuations for PACB.Check LUCD's competition here
Inogen, Inc. (NASDAQ: INGN)
PACB vs INGN Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, INGN has a market cap of 147.3M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while INGN trades at $5.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas INGN's P/E ratio is -5.98. In terms of profitability, PACB's ROE is -49.62%, compared to INGN's ROE of -0.13%. Regarding short-term risk, PACB is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for PACB.Check INGN's competition here
iCAD, Inc. (NASDAQ: ICAD)
PACB vs ICAD Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas ICAD's P/E ratio is -20.37. In terms of profitability, PACB's ROE is -49.62%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, PACB is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for PACB.Check ICAD's competition here
electroCore, Inc. (NASDAQ: ECOR)
PACB vs ECOR Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, ECOR has a market cap of 99.4M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while ECOR trades at $11.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas ECOR's P/E ratio is -6.57. In terms of profitability, PACB's ROE is -49.62%, compared to ECOR's ROE of +5.25%. Regarding short-term risk, PACB is more volatile compared to ECOR. This indicates higher risk in terms of short-term price fluctuations for PACB.Check ECOR's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
PACB vs HJLI Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas HJLI's P/E ratio is N/A. In terms of profitability, PACB's ROE is -49.62%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, PACB is more volatile compared to HJLI. This indicates higher risk in terms of short-term price fluctuations for PACB.Check HJLI's competition here
Asensus Surgical, Inc. (AMEX: ASXC)
PACB vs ASXC Comparison September 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 531.1M. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, PACB is priced at $1.83 on the NASDAQ, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -4.17, whereas ASXC's P/E ratio is -1.12. In terms of profitability, PACB's ROE is -49.62%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, PACB is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for PACB.Check ASXC's competition here